Specialty Generics Market Size, Share, and Trends 2024 to 2034

The global specialty generics market size is calculated at USD 102.92 billion in 2025 and is forecasted to reach around USD 207.25 billion by 2034, accelerating at a CAGR of 8.10% from 2025 to 2034. The North America market size surpassed USD 35.33 billion in 2024 and is expanding at a CAGR of 8.12% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : January 2025
  • Report Code : 2708
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Specialty Generics Market 

5.1. COVID-19 Landscape: Specialty Generics Industry Impact

5.2. COVID-19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Specialty Generics Market, By Type

8.1. Specialty Generics Market Revenue and Volume, by Type

8.1.1 Injectables

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Oral drugs

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Others

8.1.3.1. Market Revenue and Volume Forecast

Chapter 9. Global Specialty Generics Market, By Application

9.1. Specialty Generics Market Revenue and Volume, by Application

9.1.1. Oncology

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Inflammatory Conditions

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. Multiple Sclerosis

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Hepatitis C

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. Others

9.1.5.1. Market Revenue and Volume Forecast

Chapter 10. Global Specialty Generics Market, By End-Use 

10.1. Specialty Generics Market Revenue and Volume, by End-Use

10.1.1. Specialty Pharmacy

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Retail Pharmacy

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Hospital Pharmacy

10.1.3.1. Market Revenue and Volume Forecast

Chapter 11. Global Specialty Generics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Type

11.1.2. Market Revenue and Volume Forecast, by Application

11.1.3. Market Revenue and Volume Forecast, by End-Use

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Type

11.1.4.2. Market Revenue and Volume Forecast, by Application

11.1.4.3. Market Revenue and Volume Forecast, by End-Use

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Type

11.1.5.2. Market Revenue and Volume Forecast, by Application

11.1.5.3. Market Revenue and Volume Forecast, by End-Use

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Type

11.2.2. Market Revenue and Volume Forecast, by Application

11.2.3. Market Revenue and Volume Forecast, by End-Use

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Type

11.2.4.2. Market Revenue and Volume Forecast, by Application

11.2.4.3. Market Revenue and Volume Forecast, by End-Use

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Type

11.2.5.2. Market Revenue and Volume Forecast, by Application

11.2.5.3. Market Revenue and Volume Forecast, by End-Use

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Type

11.2.6.2. Market Revenue and Volume Forecast, by Application

11.2.6.3. Market Revenue and Volume Forecast, by End-Use

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Type

11.2.7.2. Market Revenue and Volume Forecast, by Application

11.2.7.3. Market Revenue and Volume Forecast, by End-Use

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Type

11.3.2. Market Revenue and Volume Forecast, by Application

11.3.3. Market Revenue and Volume Forecast, by End-Use

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Type

11.3.4.2. Market Revenue and Volume Forecast, by Application

11.3.4.3. Market Revenue and Volume Forecast, by End-Use

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Type

11.3.5.2. Market Revenue and Volume Forecast, by Application

11.3.5.3. Market Revenue and Volume Forecast, by End-Use

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Type

11.3.6.2. Market Revenue and Volume Forecast, by Application

11.3.6.3. Market Revenue and Volume Forecast, by End-Use

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Type

11.3.7.2. Market Revenue and Volume Forecast, by Application

11.3.7.3. Market Revenue and Volume Forecast, by End-Use

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Type

11.4.2. Market Revenue and Volume Forecast, by Application

11.4.3. Market Revenue and Volume Forecast, by End-Use

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Type

11.4.4.2. Market Revenue and Volume Forecast, by Application

11.4.4.3. Market Revenue and Volume Forecast, by End-Use

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Type

11.4.5.2. Market Revenue and Volume Forecast, by Application

11.4.5.3. Market Revenue and Volume Forecast, by End-Use

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Type

11.4.6.2. Market Revenue and Volume Forecast, by Application

11.4.6.3. Market Revenue and Volume Forecast, by End-Use

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Type

11.4.7.2. Market Revenue and Volume Forecast, by Application

11.4.7.3. Market Revenue and Volume Forecast, by End-Use

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Type

11.5.2. Market Revenue and Volume Forecast, by Application

11.5.3. Market Revenue and Volume Forecast, by End-Use

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Type

11.5.4.2. Market Revenue and Volume Forecast, by Application

11.5.4.3. Market Revenue and Volume Forecast, by End-Use

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Type

11.5.5.2. Market Revenue and Volume Forecast, by Application

11.5.5.3. Market Revenue and Volume Forecast, by End-Use

Chapter 12. Company Profiles

12.1. Teva Pharmaceuticals Industries Ltd.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Viatris Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Novartis AG (Sandoz International GmbH)

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Hikma Pharmaceuticals PLC

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Mallinckrodt

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Bausch Health Companies Inc. (Valeant Pharmaceuticals International, Inc.)

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Dr. Reddy’s Laboratories Ltd.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Endo Pharmaceuticals Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Apotex Corp.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Sun Pharmaceutical Industries Ltd.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global specialty generics market size was accounted at USD 95.12 billion in 2024 and it is expected to reach around USD 207.25 billion by 2034.

The global specialty generics market is poised to grow at a CAGR of 8.10% from 2025 to 2034.

The major players operating in the specialty generics market are Teva Pharmaceuticals Industries Ltd., Viatris Inc., Novartis AG (Sandoz International GmbH), Hikma Pharmaceuticals PLC, Mallinckrodt, Bausch Health Companies Inc. (Valeant Pharmaceuticals International, Inc.), Dr. Reddy’s Laboratories Ltd., Endo Pharmaceuticals Inc., Apotex Corp., Sun Pharmaceutical Industries Ltd., Fresenius Kabi Brasil Ltd., STADA Arzneimittel AG and Others.

The driving factors of the specialty generics market are the rising geriatric populations and the increasing prevalence of chronic illnesses.

North America region will lead the global specialty generics market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client